Monday, 16 February 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 16 February 2026
News

Innovators block biosim spread

Posted 16 February 2026 AM

The number of biosimilars subsidised on the PBS in 2024-25 grew by almost 50 per cent compared to the previous year, but the total cost to government remained almost the same, suggesting originator brands successfully defended their market share.

Pharma in Focus compared the 2023-24 financial year and 2024-25 financial year PBS Expenditure and Prescription reports to analyse the change in the cost to government of biosimilar products over the two years, although the data does not include drugs funded under efficient funding of chemotherapy.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (14)

Access & Reimbursement (1)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (5)

Other (18)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.